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The Fc region of HIV-1 Env-specific broadly neutralizing antibodies (bNAbs) is required for
suppressing viremia, through mechanisms which remain poorly understood. Here, we identify
bNAbs that exert antibody-dependent cellular cytotoxicity (ADCC) in cell culture and
kill HIV-1-infected lymphocytes through NK engagement. These antibodies target the
CD4-binding site, the glycans/V3 and V1/V2 loops on gp120, or the gp41 moiety. The
landscape of Env epitope exposure at the surface and the sensitivity of infected cells to ADCC
vary considerably between viral strains. Efficient ADCC requires sustained cell surface
binding of bNAbs to Env, and combining bNAbs allows a potent killing activity. Furthermore,
reactivated infected cells from HIV-positive individuals expose heterogeneous Env epitope
patterns, with levels that are often but not always sufficient to trigger killing by bNAbs. Our
study delineates the parameters controlling ADCC activity of bNAbs, and supports the use of
the most potent antibodies to clear the viral reservoir.
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T
wo to four years post infection, rare HIV-1-positive
patients develop a broadly serologic neutralizing
activity against various viral strains1–3. The isolation
and molecular characterization of bNAbs produced in these
individuals have allowed the identification of five major ‘sites of
vulnerability’ on the HIV Env trimer2,4,5. Passive transfer of the
most potent bNAbs provides both pre-exposure prophylaxis
and treatment in macaque and humanized mouse models3–5.
In HIV-1-infected individuals, a single infusion of the 3BNC117
bNAb, which targets the CD4-binding site on gp120, decreases
viremia for up to 28 days6. In vivo, the antiviral activity of bNAbs
results from antigen-binding site-Env interactions that block
entry of cell-free virions as well as viral cell–cell transmission7,8.
Their activity is also highly dependent on the effector functions
mediated by the Fc region, as demonstrated in animals using
Fc-mutated bNAbs9–11.
Antibody effector functions include antibody-dependent
cellular cytotoxicity (ADCC), mediated through binding of the
Fc portion of antibodies to Fc receptors (FcRs) on effector cells
including natural killer (NK) cells12–14. There is an increased
interest in understanding the role of ADCC to prevent and
control HIV-1 infection13,14. The presence of anti-Env IgG
antibodies displaying ADCC in the absence of a strong IgA
response is a main correlate of protection in the RV144 HIV-1
vaccine trial15,16. In HIV-infected individuals, the presence of
ADCC antibodies often correlates with a slow disease
progression12–14,17–19. An ADCC activity is also associated with
reduced mortality in HIV-infected infants20. Serum ADCC-
mediating antibodies target various Env epitopes including the
variable loop 3 (V3), the constant region 1 (C1) and the CD4-
induced (CD4i) region21,22 and likely exert significant immune
pressure on the virus21. The ADCC activity of some anti-Env
antibodies (including b12, 2G12, PGT126, as well as A32 that
target a CD4i epitope) has been well studied12,23–25. These
antibodies bind to Env glycoproteins at the cell surface and
mediate their killing by NK cells. Interestingly, HIV-1 partly
escapes ADCC. The HIV-1 Vpu and Nef proteins reduce the
ability of some antibodies (targeting mostly CD4i epitopes) to
perform ADCC12,23–25.
Cure strategies are aimed at targeting the latent HIV-1
reservoir within resting CD4þ T cells after viral reactivation26.
bNAbs associated with viral inducers decrease rebound in
humanized mice, through partly understood mechanisms that
may include direct elimination of infected cells27. It is thus
important to examine the competence of bNAbs to perform
ADCC, to understand the underlying mechanisms and to
determine whether ADCC-potent bNAbs may be used to purge
or reduce the size of the latent reservoir. We identify here a subset
of bNAbs that bind and kill HIV-1-infected cells through NK
engagement. Furthermore, reactivated infected cells from HIV-
positive individuals expose heterogeneous Env epitope patterns,
with levels that are sufficient to trigger ADCC by bNAbs.
Results
Identification of bNAbs that kill HIV-1 infected lymphocytes.
We examined the ADCC activity of bNAbs against HIV-1-
infected cells. We first investigated the ability of a panel of
ten anti-HIV-1 bNAbs to induce signalling through FcgRIII
(or CD16). The FcgRIII is the main receptor on NK cells that
detects antibody-opsonized targets, and initiates the signalling
that leads to ADCC. We previously showed that most of the
selected bNAbs neutralize HIV-1 cell-to-cell transmission7. These
antibodies are IgG1 and contain the same Fc region. They target
the CD4-binding site (VRC01, NIH 45–46, 3BNC117, 12A12),
the glycan-dependent V1/V2 loops (PG16), the V3 loop
(PGT121, 10–1074), the gp120/gp41 interface (8ANC195) and
the gp41 membrane-proximal external region (MPER)(10E8 and
4E10)2–5,28,29. As controls, we added two non-bNAbs antibodies,
5–25 (recognizing the gp41 immuno-dominant epitope) and
11–340 (a cross-neutralizing anti-V3 crown isolated from an
elite neutralizer)30. To determine how the antibodies bridge
HIV-infected cells to FcgRIII-expressing cells, CD4þ lymphoid
cells (MT4) infected with the prototypic R5-tropic NLAD8 or
X4-tropic NL4.3 HIV-1 were incubated with bNAbs before
co-culture with Jurkat NFAT-luc FcgRIII cells, which express an
NFAT-luciferase reporter activated by FcgRIII stimulation23.
NLAD8-infected cells induced FcgRIII stimulation with 8 out of
12 antibodies, with variable efficiencies (EC50 varying from
0.015 to 4.2 mgml 1 for the active antibodies; Fig. 1a and
Supplementary Fig. 1B). Similar results were obtained with NL4.3,
with the exception of V3-specific bNAbs, which were poorly
active (Fig. 1a and Supplementary Fig. 1A).
We then asked whether FcgRIII signalling was associated with
a killing activity of bNAbs. We first assessed the activity of
NIH45–46, to determine the optimal conditions of the assay.
CEM-NKR cells infected with NLAD8 or NL4.3 were pre-
incubated with NIH45–46 before co-culture with NK cells for 4 h.
We evaluated the disappearance of Gagþ target cells, as readout
for ADCC activity (Fig. 1b). A typical experiment showed that the
unrelated control antibody mGO53 was inactive, whereas
NIH45–46 (at 1.5 mgml 1) induced the disappearance of about
40% of NL4.3-infected cells (Fig. 1b). This disappearance was
primarily due to killing, as demonstrated by the presence of dying
Gagþ cells (Fig. 1c), and by upregulation of the degranulation
marker CD107a on NK cells (Supplementary Fig. 1C). Of note,
the disappearance of Gagþ cells was not due to the neutralization
activity of the bNAbs, as no decrease of Gagþ cells was observed
when NK cells were omitted in the co-culture (Supplementary
Fig. 1D). We also visualized the killing of infected cells using
time-lapse microscopy. The addition of 4,6-diamidino-2-
phenylindole (DAPI), which stains the nucleus of dying cells,
allowed us to monitor in real time the fate of cells infected with an
IRES-GFP-encoding NL4.3 HIV-1. In the presence of NIH45–46,
infected cells rapidly changed morphology and stained for DAPI
following interaction with NK cells (see an example Fig. 1d and
Supplementary Movie 1). Of note, the non-infected bystander
cells present in the co-culture were not killed by the bNAb
(Fig. 1d and Supplementary Movie 1).
We next evaluated the ADCC capacity of the full panel of
antibodies (Fig. 2). To facilitate comparisons, the antibodies were
first used at 1.5 mgml 1. Most of the 12 antibodies (including 6
with NLAD8 and 4 bNAbs with NL4.3) triggered a significant
disappearance of infected cells (20–50% decrease of Gagþ cells in
4 h). The most active bNAbs corresponded to those which
efficiently induced FcgRIII stimulation: NIH45–46 and 3BNC117,
which target the CD4bs, the clonally related anti-glycan/V3
antibodies 10–1074 and PGT121, and the MPER targeting 10E8.
In contrast, other bNAbs were less active (PG16, VRC01) or
inactive (12A12, 4E10 and 8ANC195). The disappearance of Gag-
expressing cells required interaction with FcRs, as demonstrated
using the L234A-L235A (LALA) mutation, which abrogates FcR
binding9,23. The LALA mutants of five bNAbs maintained their
ability to neutralize HIV-1 virions, and hence to bind Env, but
lost ADCC potency (Supplementary Fig. 2A). Altogether, there
results indicate that only a fraction of the bNAbs induces FcgRIII
stimulation and killing of HIV-infected cells.
Binding of bNAbs at the surface of HIV-1-infected T cells. To
examine the mechanism of ADCC by bNAbs, we assayed their
ability to bind HIV-1-infected cells. As previously shown with
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sera from infected individuals19,22,31, flow cytometry indicated
that the bNAbs displaying strong ADCC activity efficiently
bound (at 4 C) HIV-1-infected lymphocytes (Fig. 3a,b and
Supplementary Fig. 2B for the gating strategy). The bNAbs
primarily bound to Gagþ cells and not to bystander cells. Up to
70% of Gagþ cells exposed detectable Env epitopes, when the
antibodies were used at the highest concentration of 15 mgml 1.
The steady-state levels (corresponding to the Median
Fluorescence Intensity) varied with each bNAb (Fig. 3c). In
contrast, ADCC-inactive bNAbs 4E10 and 8ANC195 did not
detectably bind infected cells (Fig. 3). PGT121, which displayed
ADCC activity against NLAD8 and not NL4.3, selectively
bound NLAD8-infected cells. Of note, with NL4.3, a ‘diagonal’
intermediate population, which corresponded to Gag-low cells,
was detected with two antibodies (5–25 and 10E8; Fig. 3). This
diagonal population was not observed in non-infected cells.
It may correspond to cells infected at low levels, and/or to cells
which may have recently bound incoming viral particles and
expose epitopes recognized by these antibodies.
To document the binding and killing activities, we tested the
antibodies individually at concentrations varying from 0.015 to
15 mgml 1 (Fig. 4). Binding on CEM-NKR cells infected with
NLAD8 or NL4.3 was performed either at 4 C to assess the
steady-state levels of Env epitope exposure, or at 37 C to reflect
the experimental conditions of the ADCC assay. With each
antibody, the % of infected cells positive for bNAb binding
increased with the concentration and often reached a plateau at
1.5–15 mgml 1 (Fig. 4). As expected, binding was generally more
efficient at 37 C than at 4 C. This was particularly marked with
10E8, which barely bound infected cells at 4 C, but displayed
significant opsonization at 37 C. Exceptions were also observed
with 10–1074. This antibody-bound NL4.3-infected cells more
efficiently at 4 C than at 37 C. In contrast, a strong binding
occurred at both temperatures with NLAD8-infected cells. The
killing activity of the antibodies increased with the concentration
and mirrored binding at 37 C (Fig. 4). A Spearman rank analysis
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Figure 1 | Analysis of the ADCC activity of bNAbs. (a) Analysis of the
ability of bNAbs bound to infected cells to signal through FcgRIII. MT4C5
cells infected with HIV-1 (NLAD8 or NL4.3 strains) were incubated with the
indicated antibodies and with a Jurkat indicator cell line expressing FcgRIII.
Upon FcgRIII binding, activation of the NFAT transcription factor induces
luciferase. Raw results are presented in Supplementary Fig. 1. The heat map
represents the fold increase of the signal over background. (b) CEM-NKR
cells infected with HIV-1 (NL4.3 strain) were incubated with NIH45–46
bNAb or with the mGO53 isotype antibody and with NK cells. After 4 h, the
% of Gagþ CEM-NKR target cells (indicated in blue) was measured by flow
cytometry. One representative experiment (out of six) is shown. FSC,
forward scatter. (c) The viability of infected CEM-NK cells was assessed by
flow cytometry using the live/dead cell marker. One representative
experiment (out of six) is shown. (d) CEM-NKR cells infected with NL4–3
encoding IRES-GFP were incubated with NIH45–46 bNAb and plated with
primary NK cells. To distinguish dead cells, DAPI dye was added and cells
were imaged by time-lapse microscopy. The green cell represents infected
live CEM-NKR cells, and turn blue when dying (blue arrow). NK cells are
smaller in size. One representative field (corresponding to Supplementary
Movie 1) is shown. The arrow indicates a contact between CEM-NKR and
NK cells. Scale bar, 2 mm.
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Figure 2 | Identification of bNAbs that kill HIV-1-infected lymphocytes.
The 12 indicated antibodies were tested at 1.5mgml 1 on CEM-NKR cells
infected with NLAD8 or NL4.3 strains. ADCC was calculated as the
disappearance of Gagþ cells with or without antibody (N¼6–8
experiments). Each dot represents a single NK donor. Significance was
determined by comparing each antibody to mGO53; ***Po0.001;
**Po0.01; *Po0.05, Wilcoxon test).
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Figure 3 | Binding of bNAbs at the surface of HIV-1-infected lymphocytes. (a) CEM-NKR cells infected with HIV-1 (NLAD8 or NL4.3) were incubated
with the indicated bNAbs (15mgml 1) at 4 C and surface levels were analysed by flow cytometry. The numbers indicate the % of bNAbþ cells
among infected (Gagþ ) cells. One representative experiment (out of six) is shown. The gates were first set on the staining obtained with the mGO53
isotype control. For the bNAbs displaying background staining to the fraction of Gag-negative cells (PGT121 and 8ANC195), the gates were adjusted
to decrease this background. (b,c) The binding of the 12 indicated antibodies to the surface of CEM-NKR cells infected with HIV-1 NLAD8 (blue)
or NL4.3 (red) was determined by flow cytometry. The antibodies are classified according to their competence to eliminate (ADCCþ : 420%) or not
(ADCC :o20%) infected cells in the ADCC assay. (b) Results and expressed as the % of Envþ cells among Gagþ cells. (c) The median fluorescence
intensity (MFI) of staining among Gagþ cells is shown (N¼ 3 experiments; error bars indicate s.e.m. and significance was determined by comparing
stainings to non-infected (NI) cells, *Po0.05, Mann–Whitney test).
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Figure 4 | Dose–response analysis of binding of bNAbs and ADCC activity against HIV-1-infected lymphocytes. CEM-NKR cells infected with HIV-1
NLAD8 (a) or NL4.3 (b) were incubated with the indicated concentrations of antibodies at 4 or 37 C and surface levels were analysed by flow cytometry.
The numbers indicate the % of bNAbþ cells among infected (Gagþ ) cells (left axis) and the % of ADCC (right axis). ADCC y axes were adjusted for each
antibody to facilitate comparisons with the binding profile. For measurement of ADCC, HIV-1-infected CEM-NKR cells were incubated with the indicated
antibodies and with NK cells. After 4 h, the % of Gagþ CEM-NKR target cells was measured by flow cytometry. The % of ADCC was calculated as the
disappearance of Gagþ cells (N¼ 3 independent experiments for binding; killing assays were performed using at least two NK cell donors; Error bars
indicate s.e.m.).
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indicated that the two variables were often correlated
(Supplementary Table 1). Again, rare discrepancies were detected.
10–1074 potently killed cells infected with NLAD8, and not with
NL4.3, despite binding to the later at the highest concentration
tested. The same situation was observed with PG16, which poorly
bound NL4.3-infected cells but did not display detectable ADCC
activity (Fig. 4). Of note, the % of bNAbþ -infected cells (Fig. 4)
mirrored the intensity of binding (MFI), which also increased
with the concentration of antibody tested (Supplementary Fig. 3).
A dose–response analysis of the antibody concentration
demonstrated that EC50, defined as the effective concentration
mediating 50% of the maximal effect, were generally similar in the
binding (at 37 C) and killing assays (Fig. 4 and Supplementary
Table 2). In both assays, the EC50 varied from 0.2 to
415mgml 1, depending on the antibody (Fig. 4 and
Supplementary Table 2). There was a significant correlation
between the binding potency of the antibodies, at either 4 or
37 C and their killing activities against CEM-NKR cells infected
with NLAD8 or NL4.3 (Fig. 5). Similarly, the ADCC potency
was generally correlated with the neutralizing activity of the
antibodies (Fig. 5 and Supplementary Table 1). Notable
exceptions include the non-bNAb 5–25, which did not neutralize
NLAD8 or NL4.3 but displayed a potent ADCC activity against
these viruses.
To visualize the binding of bNAbs on infected cells, we
performed immunofluorescent microscopy (Supplementary
Fig. 4A) and found a co-localization of NIH45–46 with mature
Gag (p17) proteins, whereas immuno-gold staining and scanning
electron microscopy (Supplementary Fig. 4B) indicated a
preferential binding of the bNAb to viral budding sites.
Stability of bNAbs at the surface of HIV-1-infected T cells. We
then measured the cell surface stability of Env-bNAb complexes
at 37 C, an additional parameter that we suspect regulates the
sensitivity of infected cells to ADCC. We selected 10–1074 and
PG16, which both display an ADCC activity against NLAD8 but
not against NL4.3, as well as NIH45–46, which is active against
both viruses. Infected cells were stained with each bNAb at 4 C,
extensively washed and the level of remaining complexes was
measured at different times at 37 C (Fig. 6). 10–1074 bound both
NLAD8- and NL4.3-infected cells, the latter less efficiently (73
and 47% bNAbþ cells at steady-state levels, respectively, Fig. 6a).
With NLAD8, the bNAb-Env complex was relatively stable at the
cell surface, with a half-life of 2.5 h (Fig. 6a,b). This longevity was
strikingly reduced with NL4.3 (half-life of 30min), consistent
with the higher binding of 10–1074 to NL4.3-infected cells at 4 C
than at 37 C (Fig. 4). Similarly, PG16-Env complexes were less
stable with NL4.3 than with NLAD8 (Fig. 6b). In contrast,
NIH45–46 remained stably bound with the two viruses (half-life
of 2.5 h). These results, as well as those with 3BNC117 and 10E8
(Supplementary Fig. 5A), indicate that an efficient ADCC activity
is associated with a sustained presence of Env-bNAb complexes at
the cell surface. It is likely that the reduced surface stability of
some bNAb-Env complexes results from dissociation of the bNAb
due to low affinity. It will be worth exploring whether other
mechanisms, including Env endocytosis or shedding of gp120, are
also involved in the turnover of surface-bound bNAbs.
To evaluate how the affinity of a bNAb towards Env regulates
its binding and killing activity, we selected 10–1074 and the
related 10–1369 antibody. They target the same epitope, but
displaying a fivefold difference of affinity to YU-2b gp140 trimers
(KD of 4 10 9 and 2 10 8M, respectively29). As expected,
both 10–1074 and 10–1369 neutralized infection with cell-free
YU-2b virions (IC50 of 1 and 3 mgml 1, respectively,
Supplementary Fig. 5B). However, 10–1369 poorly bound to
YU-2b-infected cells, and did not trigger ADCC, when compared
with 10–1074 (Supplementary Fig. 5B). Thus, results obtained
with these two antibodies suggest that efficient killing is
associated with a stronger affinity than that necessary for
inhibiting cell-free infection.
Binding and ADCC activity of bNAbs against various HIV-1.
Primary HIV-1 isolates, including Transmitted/Founder (T/F)
viruses may be less sensitive to neutralization by bNAbs than
laboratory-adapted strains32,33. To explore the sensitivity of
primary HIV-1 to ADCC, we first measured the exposure of Env
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epitopes at the surface of CEM-NKR cells infected with five T/F
strains (WITO, THRO, REJO, CH077, RHPA)32, using five
bNAbs (Fig. 7a). The T/F viruses were selected based on their
ability to efficiently replicate in vitro. Levels of accessible Env
epitopes were lower with T/F viruses than with NLAD8. There
was a strong variability in the pattern of bNAb binding. In
contrast to NLAD8, which was recognized by all five bNAbs, cells
infected with T/F viruses generally bound only 1–3 antibodies
(Fig. 7a). There was no single bNAb recognizing all T/F viruses.
We thus mixed the five bNAbs (MixA; NIH45–46, 3BNC117,
10–1074, PG16 and 10E8, each at 1.5 mgml 1) and analysed the
ability of MixA to bind infected cells and to perform ADCC.
MixA efficiently bound cells infected with NLAD8 and, to a lower
extent, with T/F viruses (Fig. 7b), reflecting the profile observed
with individual bNAbs. Interestingly, MixA displayed an ADCC
activity against cells infected with some, but not all T/F viruses
(Fig. 7c). The killing activity against WITO, REJO and THRO was
less potent than with NLAD8, correlating with opsonization
levels. CH040 and RHPA-infected cells, which expose lower levels
of Env epitopes, were barely sensitive to killing by MixA (Fig. 7c).
MixA-bound primary CD4þ T cells infected with T/F with
variable intensities (Fig. 7d). Primary lymphocytes infected with
NLAD8, and to a lower extent with T/F viruses, were killed by
MixA (Fig. 7e). Thus, T/F HIV-1 isolates poorly expose Env
epitopes at the surface of infected lymphocytes. When combined,
bNAbs act in a complementary manner to bind infected cells,
providing increased ADCC breadth against primary HIV-1
isolates. These results are in line with experiments demonstrating
that bNAb combinations control HIV-1 replication in humanized
mice27, and block cell–cell transmission of T/F in culture34.
Activity of bNAbs against reactivated HIV-1-infected cells. We
then asked whether bNAbs could target HIV-1 produced after
stimulation of lymphocytes isolated directly from patients, as
bNAbs are potential therapeutic molecules that may reach the
reactivated viral reservoir in HIV-1-infected individuals. We
selected infected individuals under suppressive antiretroviral
treatment (viral loads o40 copies per ml, see Supplementary
Table 3 for details). We used a viral outgrowth assay, in which
phytohemagglutinin (PHA) treatment activates resting CD4þ T
cells and induces HIV-1 spread from latently infected cells35.
HIV-1 Gagþ cells started to be detected by flow cytometry at
days 7–12 post reactivation in 6 individuals (out of 20 tested,
Supplementary Fig. 6A) and increased over time, indicating that
reactivated viruses were infectious. Cell surface Env expression
was assessed with MixA or, for some of the patients, with MixB, a
second cocktail of antibodies including VRC01, PGT121, 5–25
and 11–340 (see Supplementary Fig. 6B for the gating strategy).
Binding with either MixA or MixB was observed with variable
intensities on reactivated cells from five out of the six individuals
(Fig. 8a,b and Supplementary Fig. 6C,D). In one individual
(KB12), despite ongoing viral replication, no Env signal was
detected with either Mix. We then tested the sensitivity of
reactivated cells to ADCC, using the two bNAb combinations
(Fig. 8c and Supplementary Fig. 6E). Interestingly, in cells from
four out of the five patients that bound the antibodies, an ADDC
activity was detected with either MixA or MixB, leading to the
disappearance of 10–50% of Gagþ cells. Thus, there is a strong
heterogeneity in the levels of Env epitopes expressed at the
surface of reactivated cells, which is associated with variable
susceptibility to ADCC.
Env epitope exposure was further assessed by sampling
reactivated cells from four donors with individual bNAbs present
in the two cocktails (Fig. 8d). As expected, no single antibody
bound to reactivated KB12 cells. With KB5, KB18 and KB19
samples, three to six bNAbs out of the nine tested displayed
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significant attachment to reactivated cells, each patient displaying
a different binding profile.
Discussion
We have analysed here the ADCC activity of bNAbs against
laboratory-adapted, transmitted/founder and reactivated HIV-1
derived from the viral reservoir. We report that a subset of bNAbs
effectively kills HIV-1-infected lymphocytes. All antibodies tested
contain the same Fc region, implying that the differences in their
ability to signal through FcgRIII and mediate ADCC is dependent
on their variable regions. Thus, differences in killing efficiency are
likely due to changes in binding of the antibody and accessibility
of the Fc region when bound to infected cells. Env steady-state
levels and surface stability of bNAbs regulate their ADDC
potency. We show a significant correlation between, the intensity
of antibody binding at the cell surface, the stability of this binding
at 37 C, neutralization activity and their capacity to eliminate
HIV-1-infected cells. By using the related antibodies 10–1074 and
10–1369, we further demonstrate a link between the affinity of a
given antibody to the Env trimer and its ADCC potency. Our
results extend previous work showing that antibody affinity is
related to neutralizing activity36 and provide a comprehensive
mechanistic analysis of the ADCC activity of a panel of the
newest bNAbs. We show that Env epitope exposure on infected
cells is highly variable, depending on the viral isolate. Future work
will help assess the role of viral proteins and other factors in
the modulation of epitope exposure and ADCC. PHA-activated
CD4þ T lymphocytes derived from patients’ cells expose
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sufficient amounts of Env epitopes required for recognition by
combinations of bNAbs and killing by NK cells. Our experiments
offer a mechanistic explanation as to how bNAbs associated with
viral inducers decrease rebound from latent reservoirs in
humanized mice27. We further show that induced viral
reservoirs display an extreme heterogeneity in Env epitope
exposure. This reflects the variable sensitivity of virions from
the reservoir to neutralization by bNAbs37. It would be
worthwhile to follow the landscape of epitopes longitudinally,
in order to determine whether reactivated founder viruses evolve
over time, and originates from clones or populations of cells38,39
with homogeneous or heterogeneous Env profiles. In HIV-1-
infected individuals, low-level viremia during effective highly
active antiretroviral therapy likely result from expression of
archival virus and covert viral replication40. Latent proviruses are
found predominantly in subsets of resting memory cells, which
are largely non-permissive for viral gene expression35,41,42. It will
be of interest determining whether bNAbs may kill with similar
efficiencies cells from the latent reservoir, or from a population of
lymphocytes with ongoing low-level of viral replication. This may
be achieved by sorting resting memory T cells from patients and
performing ADCC assays with various cell activators or latency-
reversing agents35. It will also be of interest to assess whether the
bNAbs may kill the actual reactivated latently infected cells before
the virus spreads to neighbouring cells. This could be performed
by visualizing killing of infected cells after viral reactivation in
humanized mouse models.
Our results directly demonstrate that bNAbs, in addition to
other immune interventions43,44, represent an efficient tool for
consideration in ‘shock and kill’ strategies aimed at purging the
viral reservoir14,26. A bNAb-based HIV-1 cure will likely require a
personalized screening of the pattern of Env epitope exposure on
reactivated cells, to determine the optimal combination of
antibodies. The reported data on differences among bNAbs in
their ability to kill HIV-1-infected lymphocytes will enable a
better understanding of the functional attributes of antibodies for
prevention and cure strategies.
Methods
Cells and viruses. CEM-NKR-CCR5 cells (referred to as CEM-NKR) obtained
from the NIH AIDS reagent programme. MT4C5 cells were derived from MT4
cells obtained from ATCC to express CCR5 (ref. 45). Primary CD4þ T cells and
NK cells were purified from peripheral blood of healthy human donors from the
Etablissement Franc¸ais du Sang (EFS) in accordance with EFS ethical guidelines by
density gradient centrifugation followed by immunomagnetic selection (Miltenyi).
Purity was 90–98% for each population. After purification, NK cells were CD16þ ,
CD32 and CD64 . For activation, primary T cells were treated with PHA
(1mgml 1) for 24 h at 37 C and then cultured in IL-2-containing medium
(50 IUml 1) for 3–5 days before use. Virus stocks were prepared by transfection of
293T cells, along with VSV-G to normalize infectivity45. Cells were infected with
HIV-1 strains NL4.3, NLAD8, YU-2b and Transmitted/Founder (CH040, RHPA,
THRO, REJO and WITO; obtained from the NIH AIDS reagent programme)45,46.
Briefly, viral inocula (0.5–5 ng of p24/106 cells for MT4C5 and CEM-NKR cells,
50–100 ng of p24/106 cells for primary CD4þ T cells) were adjusted to achieve
similar levels of Gagþ cells (around 50% in CEM-NKR cells and 15–30% in
primary CD4þ T cells) at 48 h post infection.
Antibodies. All anti-Env antibodies and bNAbs, as well as the isotype control
mGO53, were produced as recombinant monoclonal antibodies carrying the same
human IgG1 Fc region by co-transfection of 293T or 293F cells29. Antibodies were
purified by batch/gravity-flow affinity chromatography using protein G sepharose 4
fast flow beads (GE Healthcare). Absence of protein contaminations and antibody
aggregations were checked using in-gel protein Silver staining and dynamic light
scattering (DynaPro plate reader, Wyatt), respectively. All IgG preparations were
verified to be endotoxin free.
FccRIII stimulation assay. Activation of FcgRIII signalling was measured by using
a Jurkat NFAT-luc FcgRIII cell line (Promega) following the manufacturer’s
recommendations. FcgRIII signalling activates the NFAT transcription factor,
inducing expression of firefly luciferase23. HIV-1-infected MT4C5 cells were
co-cultivated with Jurkat NFAT-luc FcgRIII (ratio 1:1) for 18 h at 37 C. Cells were
then lysed and luciferase was measured on an Enspire Plate reader (Perkin-Elmer).
ADCC assay. HIV-1-infected target CEM-NKR or primary CD4 T cells were
stained using the Far Red DDAO cell tracker (Life technologies). 2–5 104 targets
were plated in U-bottom 96-well plates and incubated with antibodies (1.5 mgml 1
unless otherwise stated) for 5min at room temperature. NK cells were added in
each well (at a ratio of 1 CEM-NKR:10 NK or 1 primary CD4 T cell:1 NK,
respectively). Plates were spun 1min at 300g to promote cell contacts and
incubated at 37 C for 4 h (for primary CD4 T cells) or 6 h (for CEM-NKR cells).
Cells were then stained for intra-cellular Gag with the anti-Gag KC57 murine
monoclonal antibody45. In the indicated experiments, an anti-CD107a antibody
(clone H4A3, BD Biosciences, final dilution of 1:50) was added in the cell
co-culture to assess NK degranulation. To measure cell viability, the live/dead
fixable aqua dead cell marker (1: 1,000 in PBS, Life technologies) was added 20min
at 4 C before fixation. Data were acquired on a BD FACS CANTO II and analysed
using FlowJo software. The frequencies of Gagþ cells among Far-Redþ cells were
determined. ADCC was calculated using the following formula: 100 (% of Gagþ
target cells plus NK without antibody—% of Gagþ target cells plus effector with
antibody)/(% of Gagþ target cells plus NK without antibody). Negative values were
set to zero. The maximum values obtained in the ADCC assay was a disappearance
of B60% of Gagþ cells.
Binding and stability of bNAbs at the cell surface. Cells (0.5–2 104 per well)
were incubated 1 h at 4 C or, when stated, at 37 C with anti-Env bNAbs or with
an isotype human IgG1 control (mG053) at 15 mgml 1 (unless otherwise stated)
diluted in culture medium. Cells were then washed and incubated 30min at
4 C with an anti-human IgG1 (Hþ L) Alexa Fluor 647 (1:400 dilution, Life
technologies). Cells were then fixed with 4% paraformaldehyde and processed for
intracellular Gag staining. To measure the stability of Env-bNAb complexes at the
surface, cells were incubated 1 h at room temperature with bNAbs (15 mgml 1)
washed three times with PBS to remove unbound bNAbs and re-suspended in
warm culture medium. After the indicated times at 37 C, the levels of cell-asso-
ciated bNAbs were revealed using an anti-human IgG1 (Hþ L) Alexa Fluor 647
(1:400, Life technologies) for 30min at 4 C. Cells were then fixed with 4% par-
aformaldehyde and processed for intracellular Gag staining.
Neutralization assay. Neutralization of cell-free HIV-1 was measured using
TZM-bl cells7, which HeLa CD4þCCR5þ cells carrying an HIV-1 LTR–bgal
reporter cassette. One day before infection, 7 103 cells were plated in 96-well
plates. Cells were infected in triplicate with 1 or 5 ng Gag p24. Viruses were
incubated with the indicated bNAbs for 1 h before infection. After 36 h, cells were
lysed in PBS, 0.1% NP-40 and 5mM MgCl2 and incubated with the b-gal substrate
CPRG (Roche), before measurement of 570-nm optical density. Dose–response
inhibition curves were drawn by fitting data to sigmoid dose–response curves
(variable slope) using GraphPad Prism software. The % of inhibition was defined as
(% signal in non-treated target cells% signal in bNAb-treated cells)/(% signal in
non-treated target cells) 100. The 50% inhibitory dose (IC50) was calculated with
GraphPad Prism.
Confocal microscopy and scanning electron microscopy. Confocal microscopy
analysis was performed as described45. The following antibodies were used:
Anti-Env NIH45–46 bNAb or isotype control (15 mgml 1); anti-Gag p17 (mouse
anti-p17 ARP342, Programme EVA Centre for AIDS Reagents, 1:100 dilution) and
anti-Gag-FITC (KC57, 1:50 dilution). Acquisitions were performed on a Zeiss
LSM700 using a  63 objective. Images were analysed using FIJI software and
assembled with the Magic Montage ImageJ plugin. Immunogold staining and
scanning electron microscopy were performed as described45. The following
antibody was used: Anti-Env NIH45–46 bNAb or isotype controls (150 mgml 1).
The images were acquired with a JEOL JSM 6700F field emission scanning electron
microscope.
Live imaging. CEM-NKR cells were infected with the NL4.3-IRES-GFP virus45.
Cellular compartmentalization in microwells was achieved using 100 mm
micromesh array (Microsurfaces) stick on m-dish (Ibidi) according to the
manufacturer instruction. To fill the wells, 0.5–1.5 103 CEM-NKR cells were
seeded; the dish was then spun for 3min at 200 g. NIH45–46 bNAb (2 mgml 1)
and DAPI (to visualize dying cells) and then 0.5–1 104 NK cells were added. The
dish was transferred into a Biostation IMQ (Nikon). Ten to fifteen fields were
acquired with images taken every 2min. Image analysis was performed using
ImageJ (FIJI). One representative movie was selected.
Reactivation of HIV-1 from Highly Active Antiretroviral Therapy (HAART)-
treated patients. All patients were under successful HAART (see Supplementary
Table 3 for details). Each participant provided a written consent to participate to
the study, which was approved by the regional investigational review board
(Comite´ de Protection des Personnes Ile-de-France VII (Paris, France) and
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performed according to the European guidelines and the Declaration of Helsinki.
For each patient, 50ml of blood were collected in the presence of EDTA. Peripheral
blood mononuclear cells (PBMCs) were isolated by ficoll gradient purification and
CD4 T cells were purified as described above. For the Viral Outgrowth Assay, CD4
T cells were stimulated with PHA-M (2mgml 1, Sigma-Aldrich) in 2.5ml of
culture medium with 100UIml 1 of IL-2 (R&D) in a 12-well plate. After 24 h,
cells were washed to remove PHA-M and resuspended in 2.5ml of medium con-
taining IL-2. Every 1–2 days, 1ml of supernatant was harvested and replaced with
fresh medium. At the indicated time points, cells were evaluated for Gag expression
and bNAb binding by flow cytometry. Cells were used for ADCC experiments
when the fraction of Gagþ cells was above 5%.
Data processing and statistical analysis. Calculations were performed and
figures were drawn using Excel 2011 or GraphPad Prism 5.0. Statistical analysis
was performed using GraphPad Prism, with Wilcoxon matched paired t-tests,
Mann–Withney unpaired t-tests or extra sum-of-squares F test. Spearman
correlation coefficients (r) were calculated using GraphPad Prism.
Sample size. The size of the samples was chosen to allow a statistical analysis of
the results.
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